Simplified Chinese
Liu Jiankai Innovation Studio of Minhai Biotechnology has been awarded the “National Model Worker Team” title.
Release date:
2018-05-11
Author:
Contributed by the General Office
Source:
Abstract
On April 27, the “Striving in the New Era—Labor Writes a New Chapter” celebration marking International Labor Day and the advanced‑worker commendation conference kicked off in Daxing District, Beijing. The Liu Jiankai Innovation Studio of Beijing Minhai Biotechnology Co., Ltd. was honored with the title of “National Model Worker Team.” The “National Model Worker Team” is an honorary designation established and issued by the All-China Federation of Trade Unions, with activities centered on achieving excellence in work, service, performance, and team building.
The Liu Jiankai Innovation Studio was established in 2012, undertaking the development of novel vaccines and the upgrading of conventional vaccines for Minhai Biotechnology. It has earned recognition within the industry as an “innovation benchmark.” Since its inception, the studio has leveraged its concentration of high‑tech talent to vigorously organize diverse talent‑development initiatives; it has also tapped into the collective expertise of its scientific and technical personnel, focusing on pressing and challenging issues in vaccine R&D, collaboratively exploring innovative approaches, and driving the company’s innovative growth. To date, the studio has undertaken more than 30 national and provincial‑ministerial research projects, including seven major special programs for new drug development, and has participated in the creation of over 20 innovative vaccine candidates that boast independent intellectual property rights and cutting‑edge technological capabilities both domestically and internationally.
Staying true to our original aspiration and forging ahead with determination, the Liu Jiankai Innovation Studio will continue to uphold the spirit of innovation, focus on tackling the most challenging issues in vaccine research, develop more vaccine products with independent intellectual property rights, build a robust national health‑protection barrier, and safeguard human health!

Recommended Reading
Batch Release Status of the Company’s Products in 2026
2026-07-23
2026-07-15
2026-07-09